Heron Therapeutics Announces The FDA Acknowledged The Receipt Of The Company's Prior Approval Supplement Application For ZYNRELEF
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics announced that the FDA has acknowledged the receipt of its Prior Approval Supplement application for ZYNRELEF, with a PDUFA goal date set for September 23, 2024. If approved, the new VAN design could simplify preparation and reduce withdrawal time, potentially increasing adoption.
July 02, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heron Therapeutics' FDA application for ZYNRELEF's new VAN design has been acknowledged, with a PDUFA goal date of September 23, 2024. Approval could simplify preparation, reduce withdrawal time, and potentially increase adoption.
The FDA's acknowledgment of the PAS application and the assignment of a PDUFA date is a positive regulatory step for Heron Therapeutics. If approved, the new VAN design could simplify the preparation process and reduce withdrawal time, potentially increasing the adoption of ZYNRELEF. This could positively impact Heron's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100